TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 AMD
Advanced Micro Devices
-- 119.210 
NEWS
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Elicio Therapeutics (Nasdaq: ELTX) announced two upcoming presentations in November 2024. At the SITC 39th Annual Meeting (Nov 6-10), they will present updated T cell and Disease-Free Survival data from the AMPLIFY-7P Phase 1 trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. The Phase 2 portion of this trial is ongoing with enrollment expected to complete in Q4 2024. Additionally, at the Stand Up To Cancer Innovation Summit(Nov 4), Dr. Peter Demuth will present updates on the AMP platform and data from both AMPLIFY-7P and AMPLIFY-201 Phase 1 trials.
Elicio Therapeutics (Nasdaq: ELTX) announced two upcoming presentations in November 2024. At the SITC 39th Annual Meeting (Nov 6-10), they will present updated T cell and Disease-Free Survival data from the AMPLIFY-7P Phase 1 trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. The Phase 2 portion of this trial is ongoing with enrollment expected to complete in Q4 2024. Additionally, at the Stand Up To Cancer Innovation Summit(Nov 4), Dr. Peter Demuth will present updates on the AMP platform and data from both AMPLIFY-7P and AMPLIFY-201 Phase 1 trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment